1. What was found — a heterozygous "likely pathogenic" frameshift variant (c.3956delA, p.Tyr1319LeufsTer30) in exon 26 of the ATM gene; no clinically significant CNVs detected.
2. What the ATM gene does — its normal role in DNA double-strand break repair and genomic stability, and why loss-of-function here matters.
3. Cancer risk implications — lifetime risk increases for breast, ovarian, pancreatic, and (per the cited literature) gastric cancer given the patient's gastric cancer diagnosis, and prostate cancer risk in men.
4. Inheritance pattern — autosomal dominant transmission, 50% risk to first-degree relatives, and what that means practically for family testing.
5. Recommendations from the report — genetic counseling, cascade/Sanger testing for relatives, surveillance discussion with the physician, annual reanalysis option.
6. Test quality/limitations — coverage metrics (>200X depth, Q30), assay limitations (things NGS/MLPA can miss, pseudogene homology issues, mosaicism caveats), and what "likely pathogenic" as a classification tier actually means versus "pathogenic" or "VUS."

1. What was found — a heterozygous "likely pathogenic" frameshift variant (c.3956delA, p.Tyr1319LeufsTer30) in exon 26 of the ATM gene; no clinically significant CNVs detected.
2. What the ATM gene does — its normal role in DNA double-strand break repair and genomic stability, and why loss-of-function here matters.
3. Cancer risk implications — lifetime risk increases for breast, ovarian, pancreatic, and (per the cited literature) gastric cancer given the patient's gastric cancer diagnosis, and prostate cancer risk in men.
4. Inheritance pattern — autosomal dominant transmission, 50% risk to first-degree relatives, and what that means practically for family testing.
5. Recommendations from the report — genetic counseling, cascade/Sanger testing for relatives, surveillance discussion with the physician, annual reanalysis option.
6. Test quality/limitations — coverage metrics (>200X depth, Q30), assay limitations (things NGS/MLPA can miss, pseudogene homology issues, mosaicism caveats), and what "likely pathogenic" as a classification tier actually means versus "pathogenic" or "VUS."

The Finding

What This Means Biologically

Cancer Risk Implications

• Breast cancer: 15-40%
• Ovarian cancer: <3%
• Pancreatic cancer: 5-10%
• Prostate cancer (in men)
• Gastric cancer — cited literature (Huang et al. 2015, Helgason et al. 2015) links ATM loss-of-function variants to increased gastric cancer risk, which is directly relevant since this is his current diagnosis. This plausibly represents the underlying genetic driver of his gastric cancer.

Inheritance

Recommendations From the Report

1. Genetic counseling to interpret this in the context of his personal/family cancer history.
2. Discuss surveillance measures (e.g., earlier/more frequent screening for breast, pancreatic, prostate cancer) with his physician.
3. Cascade testing of adult family members via a targeted Sanger (mutation-specific) test — cheaper and faster than a full panel, and clarifies who else is at risk.
4. Optional annual reanalysis of the raw data, since variant classifications get updated as more evidence accumulates (this one could later be upgraded to "pathogenic" or, less likely, downgraded).

Test Quality

Caveats Worth Knowing

• "Likely pathogenic" is not the same certainty as "pathogenic" — it's a strong but not 100% confirmed causal call.
• This is a predisposition/risk result, not a diagnosis of a specific future cancer — it doesn't tell him he will get breast/pancreatic/prostate cancer, just that his baseline risk is meaningfully higher than the general population.
• The report explicitly states it is not a substitute for clinical judgment — results must be interpreted alongside his personal and family cancer history by his treating physician/genetic counselor.

• Textbook sources (Sabiston, Robbins) confirm ATM's well-established risk associations are breast (20-40%), ovarian (2-3%), pancreatic (5-10%), and prostate cancer — colorectal is not listed among ATM's classic risk associations - Sabiston Textbook of Surgery, p. 2027-2035.
• A 2025 systematic review (PMID: 40144209) found ATM status is associated with prognosis in colorectal cancer (i.e., in people who already have CRC, tumor ATM status affects outcomes/treatment response) — this is a different question from germline ATM variants causing hereditary CRC risk.
• A related 2025 case series (PMID: 41424250) looked at ATM-mutated metastatic colorectal cancer responding to DNA-damaging agents and PARP inhibitors — again mostly about tumor (somatic) ATM status guiding treatment, not germline predisposition.

Surveillance Recommendations for ATM Carriers

Key caveats

• ATM is a moderate-penetrance gene, so NCCN is more conservative here than for high-penetrance genes like BRCA1/2 - no risk-reducing surgery is recommended based on ATM status alone.
• Pancreatic screening is contingent on family history in the NCCN pathway (unlike genes such as STK11/CDKN2A, which trigger screening regardless of family history) - this makes getting an accurate family cancer history important.
• These are population-level guideline defaults. The report itself says the same thing: final surveillance decisions should be made with his treating physician/genetic counselor, incorporating his personal gastric cancer history and any family history of breast, ovarian, pancreatic, or prostate cancer.

Most Recent Clinical Guidelines for ATM Carrier Management

1. ACMG Clinical Practice Resource (2025) - the dedicated ATM guideline

• ATM confers a moderate (intermediate) risk, and actual risk should be treated as a continuous variable modified by family history, not a fixed number.
• Breast cancer: enhanced surveillance should be offered based on personalized risk estimate and country-specific guidelines; risk-reducing mastectomy is generally NOT recommended (unlike BRCA1/2).
• Prostate cancer surveillance: should be considered.
• Pancreatic cancer surveillance: should be considered based on family history assessment, ideally within a clinical trial.
• If an ATM carrier develops cancer, radiotherapy decisions should not be altered based on ATM status alone (addresses a common historical concern about radiosensitivity).
• PARP inhibitors are licensed for ATM-associated metastatic castration-resistant prostate cancer, but the evidence base is still weak.
• Bottom line from the authors: more prospective data is needed - this is a "living" area of guidance.

2. NCCN Genetic/Familial High-Risk Assessment: Breast, Ovarian, Pancreatic, and Prostate (currently V3.2026)

• Breast: annual mammography from age 40; consider adding breast MRI; no routine risk-reducing mastectomy.
• Prostate: NCCN's separate Prostate Cancer Early Detection guideline (V2.2026) supports earlier discussion of PSA screening (around age 40-45) for ATM carriers, with BRCA2 having the strongest evidence among these genes.
• Ovarian: no enhanced screening or risk-reducing surgery specifically tied to ATM.

3. Supporting recent literature

• Karlsson Q et al., Eur Urol Oncol 2021 (PRACTICAL Consortium) - established rare germline ATM variants as a prostate cancer risk factor, underpinning the NCCN prostate recommendation.
• Seca M, Narod SA, Hereditary Cancer in Clinical Practice 2024 (PMID: 39543654) - review on ATM mutations and breast cancer treatment implications, reinforcing that radiotherapy should not be withheld or modified based on ATM carrier status.
• Mukhtar TK et al., J Med Genet 2025 - large Breast Cancer Association Consortium/UK Biobank analysis specifically on the common ATM c.7271T>G variant and cancer risk, refining risk estimates for that particular variant (not necessarily the same variant found in this patient, which is a novel frameshift, c.3956delA).

What changed since our last discussion

Recent Research: ATM Variants and Gastric Cancer Outcomes

Newest and most directly relevant finding

Supporting recent evidence

• Guadagnolo D et al., Biomedicines 2023 (PMID: 37509701) — described a family with a heterozygous nonsense ATM variant and unusually high gastric cancer burden across multiple relatives, reinforcing a familial pattern of gastric cancer risk tied to ATM loss-of-function, consistent with what your report's own references (Huang 2015, Helgason 2015) already established.
• Chan KH et al., J Investig Med High Impact Case Rep 2024 (PMID: 38504422) — case report of a promising treatment response to olaparib (a PARP inhibitor) in a patient with germline ATM-mutated metastatic gastric cancer. This is clinically notable: it suggests that DNA-repair-targeted therapy (PARP inhibition) may be an option worth discussing for ATM-associated gastric cancer, particularly if the disease becomes metastatic, though this is still case-level evidence, not a trial.
• Zhang J, He P, Hereditas 2025 (PMID: 40652278) — lab-based (in silico/in vitro) study on TP53, ATM, RAD51, and BAX in gastric cancer, showing ATM dysfunction may contribute to radiotherapy resistance in gastric tumors. Relevant context, though this is mechanistic/preclinical, not a clinical outcomes study.
• Huang DS et al. 2015 and Helgason H et al. 2015 — the two original studies already cited in your report, both foundational for the ATM-gastric cancer link.

What this means for the patient